Influence of Growth Hormone Supplementation in Patients with Thin Endometrium Undergoing Frozen Embryo Transfer

作     者：Jun-Yi Yang He Li Nan Lu Lu Li Xiao-Xi Sun Yang Jun-Yi;Li He;Lu Nan;Li Lu;Sun Xiao-Xi

作者机构：Shanghai Ji Ai Genetics and IVF InstituteObstetrics and Gynecology Hospital of Fudan UniversityShanghai 200011China Key Laboratory of Female Reproductive Endocrine Related DiseasesObstetrics and Gynecology Hospital of Fudan UniversityShanghai 200011China 

出 版 物：《Reproductive and Developmental Medicine》 (生殖与发育医学（英文版）)

年 卷 期：2019年第3卷第1期

页      面：49-53页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 100211[医学-妇产科学] 10[医学] 

主　　题：Endometrial Receptivity Frozen-Thawed Embryo Transfer Growth Hormone Thin Endometrium 

摘      要：Objective:To evaluate the effect of recombinant human growth hormone(rhGH)supplementation during hormone-replacement therapy and frozen-thawed embryo transfer(FET)in patients with thin endometrium.Methods:A retrospective research was conducted on 225 patients,who underwent artificial cycle FET in Shanghai,China,between January 2016 and November 2017.Data from 245 FET cycles were analyzed,of which 184 cycles received rhGH(GH group)and 61 did not(control group).Results:Clinical pregnancy and implantation rates were significantly higher in the GH group than those in the control group(64.7%vs.49.2%,P=0.032;44.8%vs.32.8%,P=0.019,respectively).After logistic regression analysis,rhGH was considered the only significant variable that influenced clinical pregnancy rate,increasing it by 1.89-fold.On the other hand,the presence of rhGH did not seem to affect the early pregnancy loss.Conclusions:Our results indicated that simultaneous addition of rhGH could improve clinical outcomes of FET in patients with thin endometrium,particularly in patients between 30 and 34 years of age.